Farnesyltransferase Inhibitors in Breast Cancer Therapy

摘要: Farnesyltransferase inhibitors (FTIs) belong to a group of agents originally designed prevent membrane attachment Ras protein by inhibiting key step in its post-translational processing. It was thus hypothesized that FTIs would curtail the oncogenic ras-mediated proliferative and antiapoptotic signals are activated human tumors. Although is mutated only < 5% breast cancers, there multiple aberrant pathways lead activation wild-type ras signaling. Moreover, have consistently demonstrated efficacy tumors regardless their mutational status. Thus, role other targets mediating antitumor effect being elucidated. This article reviews current data on use cancer.